125 related articles for article (PubMed ID: 35085982)
1. A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer.
Cui W; Milner-Watts C; McVeigh TP; Minchom A; Bholse J; Davidson M; Yousaf N; MacMahon S; Mugalaasi H; Gunapala R; Lee R; George A; Popat S; O'Brien M
Lung Cancer; 2022 Mar; 165():34-42. PubMed ID: 35085982
[TBL] [Abstract][Full Text] [Related]
2. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
Cui W; Milner-Watts C; O'Sullivan H; Lyons H; Minchom A; Bhosle J; Davidson M; Yousaf N; Scott S; Faull I; Kushnir M; Nagy R; O'Brien M; Popat S
Eur J Cancer; 2022 Aug; 171():44-54. PubMed ID: 35704974
[TBL] [Abstract][Full Text] [Related]
3. Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC.
Cheng ML; Milan MSD; Tamen RM; Bertram AA; Michael KS; Ricciuti B; Kehl KL; Awad MM; Sholl LM; Paweletz CP; Jänne PA
JCO Precis Oncol; 2021 Nov; 5():726-732. PubMed ID: 34994618
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea.
Ahn BC; Lee S; Lee J; Lee JB; Hong MH; Lim SM; Jain S; Olsen S; Cho BC
Cancer Treat Res Commun; 2023; 36():100715. PubMed ID: 37307681
[TBL] [Abstract][Full Text] [Related]
5. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
6. Complementing Tissue Testing With Plasma Mutation Profiling Improves Therapeutic Decision-Making for Patients With Lung Cancer.
Choudhury Y; Tan MH; Shi JL; Tee A; Ngeow KC; Poh J; Goh RR; Mong J
Front Med (Lausanne); 2022; 9():758464. PubMed ID: 35223889
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
8. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
10. Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.
Yang CY; Shih JY; Liao WY; Ho CC; Hsu CL; Tsai TH; Wu SG; Lin YT; Hsu WH; Jain S; Olsen S; Yang JC; Yu CJ; Yang PC
Eur J Cancer; 2023 Nov; 193():113310. PubMed ID: 37722270
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
[TBL] [Abstract][Full Text] [Related]
12. Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls.
Esposito Abate R; Frezzetti D; Maiello MR; Gallo M; Camerlingo R; De Luca A; De Cecio R; Morabito A; Normanno N
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33348595
[TBL] [Abstract][Full Text] [Related]
13. Paired Comparison of Routine Molecular Screening of Patient Samples with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA Using Three Targeted Assays.
Barthelemy D; Lescuyer G; Geiguer F; Grolleau E; Gauthier A; Balandier J; Raffin M; Bardel C; Bouyssounouse B; Rodriguez-Lafrasse C; Couraud S; Wozny AS; Payen L
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900363
[TBL] [Abstract][Full Text] [Related]
14. Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy.
Garcia-Pardo M; Czarnecka K; Law JH; Salvarrey A; Fernandes R; Fan J; Corke L; Waddell TK; Yasufuku K; Donahoe LL; Pierre A; Le LW; Ghumman N; Liu G; Shepherd FA; Bradbury P; Sacher A; Stockley T; Pal P; Rogalla P; Tsao MS; Leighl NB
Ther Adv Med Oncol; 2022; 14():17588359221126151. PubMed ID: 36158638
[TBL] [Abstract][Full Text] [Related]
15. The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer.
Laufer-Geva S; Rozenblum AB; Twito T; Grinberg R; Dvir A; Soussan-Gutman L; Ilouze M; Roisman LC; Dudnik E; Zer A; Rotem O; Lanman RB; Peled N
J Thorac Oncol; 2018 Nov; 13(11):1705-1716. PubMed ID: 30121392
[TBL] [Abstract][Full Text] [Related]
16. Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study.
Smyth LM; Reichel JB; Tang J; Patel JAA; Meng F; Selcuklu DS; Houck-Loomis B; You D; Samoila A; Schiavon G; Li BT; Razavi P; Piscuoglio S; Reis-Filho JS; Taylor BS; Baselga J; Solit DB; Hyman DM; Berger MF; Chandarlapaty S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250397
[TBL] [Abstract][Full Text] [Related]
17. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
18. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
19. Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non-Small-Cell Lung Cancer: A Multicenter Case Series.
Jacobs MT; Mohindra NA; Shantzer L; Chen IL; Phull H; Mitchell W; Raymond VM; Banks KC; Nagy RJ; Lanman RB; Christensen J; Patel JD; Clarke J; Patel SP
JCO Precis Oncol; 2018 Nov; 2():1-10. PubMed ID: 35135131
[TBL] [Abstract][Full Text] [Related]
20. Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.
Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Trejo Rosales R; Rojas L; Cruz-Rico G; Nagy R; Cabrera L; Vargas C; Saam J; Barrón F; Arrieta O
Oncology; 2021; 99(8):539-546. PubMed ID: 33902046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
